Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 192 shares at $64.26 ($12K) on 2026-10-09, disclosed to the SEC on 2026-10-13.
Scheduled sale ($12k) by Executive VP AND CLO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| PTCT | SELL | 2026-07-08 | $432K | — | Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |
| PTCT | SELL | 2026-05-19 | $203K | — | Filing → |